Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...